Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of this study is to characterize the safety, tolerability and plasma pharmacokinetic (PK) profile of TAK-915 when administered as single and multiple oral suspension doses at escalating dose levels in healthy participants, including elderly participants.
Epistemonikos ID: 911ecae7785187b5d15d93b8e2bbf30e0cd92793
First added on: May 12, 2024